CAR-T 细胞治疗指南：研发、现状与未来前景

A guide to CAR T cell therapies: development, current status and future prospects.

功能基因组学指导的血液系统恶性肿瘤 CAR-T 与 CAR-NK 治疗设计：使细胞工程与免疫逃逸及微环境耐药相匹配

Functional genomics-guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and mi

一种以耐药为导向的策略可能有助于使工程化细胞疗法的设计与高危血液系统恶性肿瘤中治疗失败的主要机制相一致。未来的 CAR-T 和 CAR-NK 开发不应仅仅增加工程化复杂性，而应将每一处改造与可测量的耐药机制、可行的生物标志物以及可在临床中检验的获益联系起来。在耐药匹配的细胞免疫治疗能够广泛整合进入临床实践之前，前瞻性验证、基因组安全性评估、生产一致性以及长期监测将是必不可少的。

超越耗竭：用于血液肿瘤下一代免疫治疗的 T 细胞适应性

Beyond exhaustion: T cell fitness for next generation of immunotherapy for hematological cancer.

CRISPR 工程化微生物组：活体疗法彻底改变血液肿瘤免疫治疗

CRISPR-engineered microbiome: living therapeutics revolutionize blood cancer immunotherapy.

CAR-T 细胞治疗在克服血液系统恶性肿瘤耐药与拓展靶点中的新兴应用：近期研究启示

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

CAR-T 细胞基因治疗的综合评价：追溯其革命性临床突破与迈向下一代工程的进展

A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engin

基于这些进展，我们假设 CAR-T 疗法正经历从单靶点细胞毒性向多功能、可编程框架的范式转变，该框架能够克服耐药性、增强安全性，并实现实体瘤的有效渗透。

解析多发性骨髓瘤的免疫治疗耐药：遗传学见解与克服耐药的策略

Decoding immunotherapy resistance in multiple myeloma: genetic insights and approaches to counter resistance.

血液系统恶性肿瘤治疗的创新方法：CRISPR 工程化微生物组沿肠-免疫轴在免疫治疗开发中的作用

Innovative approaches in the treatment of hematologic malignancies: the role of CRISPR-engineered microbiomes along the gut-immune axis in immunothera

靶向 BCMA/CD47 的通用型 CAR-T 细胞在多发性骨髓瘤中展现出优异的抗肿瘤活性

BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.

本研究表明，靶向 BCMA/CD47 的 UCAR-T 细胞在体外和体内均表现出对 MM 强大的抗肿瘤活性，这为开发治疗多发性骨髓瘤的新型“现成”细胞免疫疗法提供了潜在策略。